Hydroxyurea for β-thalassaemia major

Saqib H. Ansari, Zohra S. Lassi, Salima M. Ali, Syed Omair Adil, Tahir S. Shamsi

Research output: Contribution to journalArticle

2 Citations (Scopus)


This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objective is to review the safety of hydroxyurea with regards to severe adverse effects in people with β-thalassaemia major. The second objective is to review the efficacy of hydroxyurea in reducing or ameliorating the requirement of blood transfusions in people with β-thalassaemia major.

Original languageEnglish
Article numberCD012064
JournalCochrane Database of Systematic Reviews
Issue number1
Publication statusPublished - 29 Jan 2016

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Ansari, S. H., Lassi, Z. S., Ali, S. M., Adil, S. O., & Shamsi, T. S. (2016). Hydroxyurea for β-thalassaemia major. Cochrane Database of Systematic Reviews, 2016(1), [CD012064]. https://doi.org/10.1002/14651858.CD012064